azvudine + trimethoprim + sulfamethoxazole

This entry refers to a combination of the nucleoside analog azvudine and the antibiotic trimethoprim-sulfamethoxazole; however, clinical and pipeline data from Genuine Biotech indicate that the intended therapeutic combination for lymphoma is **azvudine plus cyclophosphamide (CTX)**. Azvudine is a small molecule DNA synthesis inhibitor and immunomodulator that terminates DNA chain elongation in malignant cells. In the lymphoma program, it is combined with cyclophosphamide, an alkylating agent that cross-links DNA, to achieve synergistic anti-tumor effects. Preclinical studies of the azvudine/cyclophosphamide combination demonstrated complete tumor elimination in lymphoma models. Trimethoprim-sulfamethoxazole is typically used as prophylaxis against opportunistic infections (such as Pneumocystis pneumonia) in immunocompromised patients but is not the primary chemotherapy agent in this regimen.

Brand names

BactrimSeptra

Other names

Azvudine/CTXAzvudine + chemotherapyazvudine + trimethoprim-sulfamethoxazole-Genuine Biotech-DNA (Azvudine)-chemotherapy (non-specific)-combination therapy (small molecule + chemotherapy)-Lymphoma